Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler

Pharmaceutical Research

Volumn 32, Issue 6, 2015, Pages 2144-2153

  Haghi, Mehra ^a,d   Saadat, Alessandro ^b   Zhu, Bing ^a   Colombo, Gaia ^b   King, Gregory ^c   Young, Paul M ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Andersen cascade impactor; Calu 3; Epithelial transport; Mucus

Indexed keywords

CLARITHROMYCIN; FLUORESCEIN SODIUM; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; IL8 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; SOLUTION AND SOLUBILITY;

APPARENT PERMEABILITY; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LOW DRUG DOSE; LUNG ALVEOLUS EPITHELIUM CELL; METERED DOSE INHALER; PRIORITY JOURNAL; SHORT COURSE THERAPY; CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; EQUIPMENT DESIGN; IMMUNOLOGY; IMPEDANCE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; MUCUS; PERMEABILITY; PRESSURE; SECRETION (PROCESS); SOLUTION AND SOLUBILITY; TIME FACTOR;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; EPITHELIAL CELLS; EQUIPMENT DESIGN; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-8; LUNG; METERED DOSE INHALERS; MUCUS; PERMEABILITY; PHARMACEUTICAL SOLUTIONS; PRESSURE; TIME FACTORS;

EID: 84934979662     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1605-y     Document Type: Article

References (53)

1. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmon. 2001;31:464-73.
2. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1990;34(5):863-70.
3. Kawasaki S, Takizawa H, Ohtoshi T, Takeuchi N, Kohyama T, Nakamura H, et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother. 1998;42(6):1499-502.
4. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxininduced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J. 1995;8(9):1451-7.
5. Konno S, Adachi M, Asano K, Okamoto K, Takahashi T. Antiallergic activity of roxithromycin: inhibition of interleukin-5 production from mouse T lymphocytes. Life Sci. 1993;52(4):L25-30.
6. Hardy RD, Rios AM, Chavez-Bueno S, Jafri HS, Hatfield J, Rogers BB, et al. Antimicrobial and immunologic activities of clarithromycin in amurinemodel of Mycoplasma pneumoniae-induced pneumonia. Antimicrob Agents Chemother. 2003;47(5):1614-20.
7. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-6.
8. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, et al. Erythromycin and clarithromycin attenuate cytokineinduced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J. 1998;12(1):57-63.
9. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest. 1994;106(4):1116-23.
10. Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. Mediat Inflamm. 2004;13(5-6): 313-9.
11. Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S-50. quiz 51S.
12. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol. 2008;8(3):286-91.
13. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, et al. Clarithromycin suppresses lipopolysaccharideinduced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother. 2002;49(5):745-55.
14. Kanoh S, Rubin BK. Mechanismof action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590-615.
15. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediat Inflamm. 2004;13(2):111-7.
16. Ordonez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol. 2001;32(1):29-37.
17. Robinson P, Schechter MS, Sly PD, Winfield K, Smith J, Brennan S, et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. Pediatr Pulmonol. 2012;47(6):551-7.
18. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebocontrolled trial. Lancet. 2012;380(9842):660-7.
19. Valery PC, Morris PS, Byrnes CA, GrimwoodK, Torzillo PJ, Bauert PA, et al. Long-term azithromycin for Indigenous children with noncystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(8):610-20.
20. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The bless randomized controlled trial. JAMA. 2013;309(12):1260-7.
21. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005;99(2):208-15.
22. Seemungal TA, Wilkinson TM, Hurst JR, PereraWR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-47.
23. Beigelman A, Gunsten S, Mikols CL, Vidavsky I, Cannon CL, Brody SL, et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest. 2009;136(2):498-506.
24. Ekici A, Ekici M, Erdemoglu AK. Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma Official J Assoc Care Asthma. 2002;39(2):181-5.
25. Jouneau S, Kerjouan M, Caulet-Maugendre S, Guillot S, Meunier C, Desrues B, et al. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. Respir Int Rev Thoracic Dis. 2013;85(2):156-9.
26. Yokota S, Okabayashi T, Hirakawa S, Tsutsumi H, Himi T, Fujii N. Clarithromycin suppresses human respiratory syncytial virus infection-induced Streptococcus pneumoniae adhesion and cytokine production in a pulmonary epithelial cell line. Mediat Inflamm. 2012;2012:528568.
27. Amado-Rodriguez L, Gonzalez-Lopez A, Lopez-Alonso I, Aguirre A, Astudillo A, Batalla-Solis E, et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. Respir Res. 2013;14(1):52.
28. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131(2):466-73.
29. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;290(1):L75-85.
30. Shinkai M, López-Boado YS, Rubin BK. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother. 2007;59(6):1096-101.
31. Labiris N, Dolovich M. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmaco. 2003;56(6):588-99.
32. Courrier H, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev™ Ther Drug Carrier Syst. 2002;19(4-5):425-98.
33. Zhu B, Traini D, Chan H-K, Young PM. The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. Drug Dev Ind Pharm. 2013;39(11):1625-37.
34. Zhu B, Traini D, Lewis DA, Young P. The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties. Colloids Surf A PhysicochemEng Asp. 2014;443: 345-55.
35. Gupta A, Stein SW, Myrdal PB. Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers. J Aerosol Med. 2003;16(2):167-74.
36. Saadat A, Zhu B, Haghi M, King G, Colombo G, Young P, et al. The Formulation, chemical and physical characterization of clarithromycin-based macrolide solution pressurised metered dose inhaler Journal of Pharacy and Pharmacology. 2013;In Press.
37. Fiegel J, Ehrhardt C, Schaefer UF, LehrCM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res. 2003;20(5):788-96.
38. Haghi M, Traini. D, Young P. In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers Pharm Res. 2013;In Press.
39. Scalia S, Haghi M, Losi V, Trotta V, Young PM, Traini D. Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery. Eur J Pharm Sci. 2013;49(2):278-85.
40. Kreda SM, Okada SF, van Heusden CA, O'Neal W, Gabriel S, Abdullah L, et al. Coordinated release of nucleotides and mucin from human airway epithelial Calu-3 cells. J Physiol. 2007;584(1):245-59.
41. Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm. 2010;36(10):1207-14.
42. Vllasaliu D, Fowler R, Garnett M, Eaton M, Stolnik S. Barrier characteristics of epithelial cultures modelling the airway and intestinal mucosa: a comparison. Biochem Biophys Res Commun. 2011;415(4):579-85.
43. Tewes F, Paluch KJ, Tajber L, Gulati K, Kalantri D, Ehrhardt C, et al. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery. Eur J Pharm Biopharm. 2013;85(3 Pt A):604-13.
44. Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008;14(1):31-8. doi:10.1097/MCP.0b013e3282f19846.
45. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int Off J Jpn Soc Allergol. 2008;57(1):1-10.
46. Asgrimsson V, Gudjonsson T, Gudmundsson GH, Baldursson O. Novel Effects of Azithromycin on Tight Junction Proteins in Human Airway Epithelia. Antimicrob Agents Chemother. 2006;50(5):1805-12.
47. Randell SH, Boucher RC. Effective Mucus Clearance Is Essential for Respiratory Health. Am J Respir Cell Mol Biol. 2006;35(1):20-8.
48. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In Vivo and In Vitro Effects of Macrolide Antibiotics on Mucus Secretion in Airway Epithelial Cells. Am J Respir Crit Care Med. 2003;168(5): 581-7.
49. Kaneko Y, Yanagihara K, Seki M, Kuroki M, Miyazaki Y, Hirakata Y, et al. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol. 2003;285(4):L847-53.
50. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31(1):12-20.
51. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J. 1999;13(2):361-4.
52. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Antiinflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006;350(4):977-82.
53. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, et al. Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells. Am J Respir Crit Care Med. 1997;156(1):266-71.